Galapagos NV to Present In Vitro Data at ACR Convergence 2025

Galapagos NV announced that it will present new in vitro pharmacological data for its selective TYK2 inhibitor, GLPG3667, at the American College of Rheumatology (ACR) Convergence 2025. The data suggests differentiation from other TYK2 inhibitors at their clinical dose regimens. Key findings include inhibition of the IFN-α and IL-23 pathways, comparable to the currently approved TYK2 inhibitor, and more pronounced inhibition of the IL-12 pathway. GLPG3667 showed no measurable inhibition of IL-10-mediated signaling up to the highest concentration tested. The data will be presented in a poster session on October 26, 2025. GLPG3667 is currently in two Phase 3-enabling studies for systemic lupus erythematosus (SLE) and dermatomyositis (DM).